Comparative Pharmacology
Head-to-head clinical analysis: ANGIO CONRAY versus MAGNEVIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGIO CONRAY versus MAGNEVIST.
ANGIO-CONRAY vs MAGNEVIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angio-Conray (iothalamate meglumine) is a radiopaque contrast agent that attenuates X-rays, providing vascular opacification for angiographic procedures.
Gadopentetate dimeglumine is a paramagnetic contrast agent that shortens T1 and T2 relaxation times in tissues where it accumulates, enhancing signal intensity on T1-weighted magnetic resonance imaging (MRI). It distributes extracellularly and does not cross the intact blood-brain barrier, but accumulates in areas of disrupted barrier or abnormal vascularity.
Intravenous: 0.5-1 mL/kg (maximum 100 mL) of a 60% solution for computed tomography; intra-arterial: varies by procedure, typically 5-80 mL of 60% or 76% solution.
0.2 mL/kg (0.1 mmol/kg) intravenously, up to 0.6 mL/kg (0.3 mmol/kg) for certain indications, with a maximum of 20 mL per dose.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours; prolonged in renal impairment.
Terminal elimination half-life in patients with normal renal function is approximately 1.6 hours. In patients with impaired renal function, half-life is prolonged (up to 30 hours with GFR <30 mL/min).
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%.
Renal excretion of unchanged gadopentetate dimeglumine accounts for approximately 99% of the administered dose within 72 hours. Biliary/fecal excretion is negligible (<0.5%).
Category C
Category C
Contrast Agent
Contrast Agent